Drug Discovery

Erytech, Queen’s University to advance eryminase program

Erytech Pharma and the Queen’s University in Canada have entered into a research collaboration to advance the preclinical development of the former’s eryminase program specifically for the treatment of arginase-1 deficiency.

Daiichi Sankyo, Max Planck and Lead Discovery enter into cancer research collaboration

Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.

Broad Institute of MIT and Harvard joins discussions to create global CRISPR-Cas9 licensing pool

The Broad Institute of MIT and Harvard has joined discussions to form a non-exclusive CRISPR-Cas9 joint licensing pool coordinated by MPEG LA, an organization that operates patent pool licensing programs in various institutions and countries.

Shield, Ewopharma partner to commercialize Feraccru in Switzerland

Shield Therapeutics and Ewopharma have entered into an exclusive sale, supply, distribution and marketing agreement for Feraccru in Switzerland.

Celgene, BeiGene to advance PD-1 inhibitor for solid tumor cancers

Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.

Alexion signs funding deal with NICE and NHS England for Strensiq

Alexion Pharmaceuticals has signed a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age.

CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies

CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.

Servier, Transgene to apply viral vectorization technology to engineering of allogenic CAR-T

Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.

NHS patients in England getting early access to new drugs for lung cancer and sarcoma

NICE's Cancer Drugs Fund (CDF) is driving early access to new drugs for lung cancer and sarcoma for NHS patients in England.